Guide — Oncology
Prostate Cancer Nursing Care
The most common non-skin cancer in men — and usually slow-growing. Much of nursing care is helping patients navigate PSA screening decisions, telling it apart from BPH, and managing the urinary and sexual side effects of treatment.
9 min read · Oncology
Educational use only. Screening and treatment decisions are individualized and provider-directed, made through shared decision-making. This guide is educational background for nursing care. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
Overview
Prostate cancer is usually a slow-growing adenocarcinoma arising in the peripheral zone of the gland. Because it’s often indolent, many men — especially older patients with low-risk disease — are managed with active surveillance rather than immediate treatment. When it does spread, it characteristically goes to bone (causing bone pain and pathologic fractures). Growth is androgen-driven, which is why hormone (androgen deprivation) therapy is a mainstay for advanced disease.
Key Concepts
Risk & presentation
Risk rises with age, family history/BRCA, and African American race (higher incidence and mortality). Early disease is usually asymptomatic; later it may cause urinary symptoms similar to BPH (hesitancy, weak stream, nocturia) or, with metastasis, bone pain.
Screening: PSA & DRE
PSA (prostate-specific antigen) and the digital rectal exam (DRE) are screening tools, but PSA also rises with BPH, prostatitis, and after manipulation — so screening is a shared decision weighing the risk of overdiagnosis/overtreatment. Diagnosis is confirmed by biopsy with a Gleason score.
Prostate cancer vs BPH
Both can cause obstructive urinary symptoms. On DRE, BPH feels smooth, rubbery, symmetrically enlarged; cancer is classically a hard, irregular nodule. PSA tends to be higher with cancer (see the BPH vs prostate cancer chart).
Treatment
Options by risk: active surveillance, radical prostatectomy, radiation (external beam or brachytherapy seeds), and androgen deprivation therapy (ADT) (LHRH agonists/antagonists, antiandrogens) for advanced disease. Key side effects: urinary incontinence and erectile dysfunction (surgery/radiation); hot flashes, osteoporosis, and metabolic/cardiac risk (ADT).
Assessment Findings
Assess urinary symptoms (hesitancy, frequency, nocturia, weak stream, retention), review PSA trend and DRE findings, and screen for bone pain suggesting metastasis. After prostatectomy, monitor urinary continence and the catheter; with ADT, assess hot flashes, bone health, and cardiometabolic status. Assess the impact on sexual function and mood.
Nursing Priorities
Post-prostatectomy care
Maintain catheter patency, monitor urine output and for bleeding, and teach pelvic floor (Kegel) exercises to improve continence. Prepare patients for a period of incontinence and possible erectile dysfunction.
Radiation & brachytherapy safety
For brachytherapy seed implants, follow radiation safety/precautions per policy; for external beam, provide skin and bowel/bladder side-effect care.
Manage ADT effects
Address hot flashes, support bone health (calcium/vitamin D, weight-bearing exercise, bone-density monitoring), and monitor cardiometabolic risk. Reinforce adherence.
Watch for metastatic complications
Bone metastasis can cause pain, fractures, and spinal cord compression — report new back pain, weakness, or bowel/bladder changes urgently.
Therapeutic Communication Considerations
Men may be reluctant to discuss urinary and sexual function. Create privacy, normalize these concerns, and address incontinence and erectile dysfunction openly — they strongly affect quality of life and treatment choice. Support shared decision-making about screening and treatment (including active surveillance), present options without pressure, and include partners as the patient wishes.
Patient & Family Education
Explain PSA screening as a shared decision (benefits and the overtreatment risk), starting around age 50 (earlier for higher-risk men). Teach Kegel exercises and continence strategies after surgery, brachytherapy safety precautions, and ADT side-effect management (hot flashes, bone health). Reinforce reporting new bone pain or neurologic changes, and the importance of follow-up PSA surveillance.
NCLEX Pearls
- ✦Prostate cancer is usually slow-growing; low-risk disease is often managed with active surveillance.
- ✦PSA + DRE are screening tools, but PSA also rises with BPH/prostatitis — screening is a SHARED decision.
- ✦DRE: BPH = smooth, rubbery, symmetric; cancer = hard, irregular nodule.
- ✦It spreads to BONE — report new bone pain, back pain with weakness, or bowel/bladder changes (spinal cord compression).
- ✦Main treatment side effects: urinary incontinence and erectile dysfunction; teach Kegel exercises after prostatectomy.
- ✦Androgen deprivation therapy causes hot flashes and bone loss — support bone health and adherence.
Related Resources
Standards & sources
Fact-checked Jun 21, 2026This page is written to align with Oncology Nursing Society (ONS) · National Comprehensive Cancer Network (NCCN) · American Society of Clinical Oncology (ASCO). It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →